NCT03326388View on ClinicalTrials.gov

Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 26, 2019

Primary Completion Date

February 14, 2024

Study Completion Date

February 14, 2024

Conditions
Neurofibromatosis Type 1Plexiform NeurofibromaOptic Nerve Glioma
Interventions
DRUG

Selumetinib

Selumetinib Intermittent Dosing

Trial Locations (2)

wc1n 1eh

Great Ormond Street Hospital for Children NHS Foundation Trust, London

WC1N 3JH

Great Ormond Street Hospital NHS Foundatin Trust, London

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Great Ormond Street Hospital for Children NHS Foundation Trust

OTHER